Sabahattin MUHTAROĞLU, Kürşad ÜNLÜHİZARCI, Didem BARLAK KETİ

Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot

Background/aim: To investigate serum ischemia-modified albumin (IMA), oxidized low-density lipoprotein (ox-LDL) levels, and paraoxonase 1 (PON1) activity in patients with diabetic foot. Materials and methods: Thirty patients with diabetes mellitus (DM), 30 patients with diabetic foot (29 and 27 of these patients had type 2 DM, respectively), and 30 healthy volunteers as the control group were included in the study. The patients with diabetic foot were divided into 2 groups, as those who had or had not undergone lower extremity amputation. Serum PON1 activity, ox-LDL, and IMA levels were measured. Results: Serum PON1 activity was lower (P < 0.05) and ox-LDL levels were higher (P < 0.05) in the diabetic foot group than in the control and diabetes groups. Albumin-adjusted IMA values were higher (P < 0.001) in the diabetic foot group compared to the diabetes group. The postamputation levels of IMA were decreased compared to the preamputation condition (P < 0.05). Conclusion: The low activity of PON1 and the high levels of ox-LDL and IMA may play an important role in the pathogenesis of diabetic foot. The use of these parameters in the follow-up of patients with DM may prevent the development of diabetic foot. In order to reach a definitive judgment, further studies with a larger number of subjects are necessary

PDF

___

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl. 1): 8190.
2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 15451551.
3. Frykberg RG, Zgonis T, Armstrong DG, Driver WR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM et al. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg 2006; 45: 168.
4. Chapman MJ. The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes. Diabetes Vasc Dis Re 2006; 3 (Suppl. 1): 69.
5. Renie G, Maingrette F, Li L. Diabetic vasculopathy and the lectin-like oxidized low-density lipoprotein receptor-1 (LOX- 1). Curr Diabetes Rev 2007; 3: 103110.
6. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscl Throm Vas 2001; 21: 473480.
7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, PrimoParmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101: 15811590.
8. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes-review and clinical implications. Clin Chem Lab Med 2011; 49: 177184.
9. Lixanduru D, Mohora M, Coman A, Stoian I, Van Gils C, Aerts P, Manuel-Y-Keenoy B. Diet and paraoxonase 1 enzymatic activity in diabetic foot patients from Romania and Belgium: favorable association of high flavonoid dietary intake with arylesterase activity. Ann Nutr Metab 2010; 56: 294301.
10. An WS, Kim SE, Kim KH, Bae HR, Rha SH. Associations between oxidized LDL to LDL ratio, HDL and vascular calcification in the feet of hemodialysis patients. J Korean Med Sci 2009; 24 (Suppl. 2): 115120.
11. Wagner FW Jr. The diabetic foot. Orthopedics 1987; 10: 163 172.
12. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214227.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
14. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311315.
15. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified testing: adjustment for serum albumin [letter]. Clin Chem Lab Med 2007; 45: 261 262.
16. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pr 2010; 87: 414.
17. Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, Fasanmade A, Moropane M. Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J 2008; 98: 614 617.
18. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, Re L, Giuliani A, Candelario-Jalil E, Alvarez H, Fernández Montequín JI, León OS. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005; 523: 151161.
19. El-Mesallamy HO, Hamdy NM, Ezzat OA, Reda AM. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Invest Med 2011; 59: 12331238.
20. Jude EB, Tentolouris N, Appleton I, Anderson S, Boulton AJM. Role of neuropathy and neuroischemic diabetic foot ulcers. Wound Repair Regen 2001; 9: 353359. 21. Weigelt C, Rose B, Poschen U, Ziegler D, Friese G, Kempf K, Koenig W, Martin S, Herder C. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 2009; 32: 14911496.
22. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, Liberatoscioli L, Gnasso A, Schillaci G, Mannarino E. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349354.
23. Kasprzak M, Iskra M, Majewski W, Wielkoszynski T. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs. Clin Biochem 2009; 42: 5056.
24. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diabetes Vasc Dis Re 2007; 4 (Suppl. 3): 58.
25. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman M, Navab M. Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 27582767.
26. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteqhamati A, Morteza A, Jamali A, Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010; 45: 321327.
27. Unluhizarci K, Muhtaroglu S, Kabak S, Bayram F, Kelestimur F. Serum lipoprotein (a) levels in patients with diabetic foot lesions. Diabetes Res Clin Pr 2006; 71: 119123.
28. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemiamodified albumin level in type 2 diabetes mellitus preliminary report. Dis Markers 2008; 24: 311317.
29. Ukinc K, Eminagaoglu S, Ersoz HO. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 2009; 36: 425432.
30. Turk A, Nuhoglu I, Mentese A, Karahan SC, Erdol H, Erem C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina 2011; 31: 602608.
31. Gunduz A, Mentese A, Turedi S, Karahan SC, Mentese U, Eroglu O, Turkmen S, Turan I, Ucar U, Russell L et al. Serum ischemia-modified albumin in critical lower limb ischaemia. Emerg Med J 2008; 25: 351353.
32. Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics 2011; 66: 16771680.
33. Gaze DC, Crompton L, Collinson P. Ischemia-modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Prin Pract 2006; 15: 322324.
34. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47: 464470.
35. Sbaroni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 2006; 48: 24822484.
36. Nather A, Bee CS, Huak CY, Chew CLL, Lin CB, Neo S, Sim EY. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complicat 2008; 22: 7782.
37. Shojaiefard A, Khorgami Z, Larijani B. Independent risk factors for amputation in diabetic foot. Int J Diabetes Dev C 2008; 28: 3237.